Scholarlink

<p>This study analyzed contemporary trends in major salivary gland carcinoma (MSGC) incidence in the United States from 2000 to 2022 using the SEER 17 Registries. Age-adjusted incidence rates (IRs) per 1,000,000 persons and temporal trends were evaluated using annual percent change (APC) and average APC (AAPC). A total of 20,522 MSGC cases were identified, with an overall IR of 10.4 and a significant increasing trend over time (APC = 0.42%, <i>P</i> = 0.015). Incidence increased particularly among females (APC = 0.81%, <i>P</i> = 0.002), older age groups (60–79 years: APC = 0.40%, <i>P</i> = 0.036; ≥80 years: APC = 1.12%, <i>P</i> = 0.010), the Black population (APC = 0.80%, <i>P</i> = 0.029), and parotid gland primaries (APC = 0.40%, <i>P</i> = 0.023). In stage-specific analyses restricted to 2004–2022, localized disease also increased significantly (APC = 0.89%, <i>P</i> = 0.002). Among major histologic subtypes, adenocarcinoma, not otherwise specified, showed a significant decreasing trend (AAPC=–3.33%, <i>P</i> &lt; 0.001), whereas salivary duct carcinoma (AAPC = 10.41%, <i>P</i> &lt; 0.001) and carcinoma ex pleomorphic adenoma (APC = 2.20%, <i>P</i> = 0.022) showed increasing trends. Female-focused subgroup analyses demonstrated increasing incidence in both age groups: females aged ≥ 60 years (APC = 0.64%, <i>P</i> = 0.012) and those aged &lt; 60 years (APC = 0.88%, <i>P</i> = 0.009). Mucoepidermoid carcinoma also exhibited an increasing trend among females (APC = 0.87%, <i>P</i> = 0.016). These findings indicate a significant increase in MSGC incidence in the US, with distinct demographic and clinicopathological patterns.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Trends and characteristics of major salivary gland carcinoma incidence in the United States, 2000–2022

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月23日

查看全文
  • Dongbin Ahn,
  • Theresa Guo,
  • Jingjing Hu,
  • Tomoya Kurokawa,
  • Joseph Califano

摘要

This study analyzed contemporary trends in major salivary gland carcinoma (MSGC) incidence in the United States from 2000 to 2022 using the SEER 17 Registries. Age-adjusted incidence rates (IRs) per 1,000,000 persons and temporal trends were evaluated using annual percent change (APC) and average APC (AAPC). A total of 20,522 MSGC cases were identified, with an overall IR of 10.4 and a significant increasing trend over time (APC = 0.42%, P = 0.015). Incidence increased particularly among females (APC = 0.81%, P = 0.002), older age groups (60–79 years: APC = 0.40%, P = 0.036; ≥80 years: APC = 1.12%, P = 0.010), the Black population (APC = 0.80%, P = 0.029), and parotid gland primaries (APC = 0.40%, P = 0.023). In stage-specific analyses restricted to 2004–2022, localized disease also increased significantly (APC = 0.89%, P = 0.002). Among major histologic subtypes, adenocarcinoma, not otherwise specified, showed a significant decreasing trend (AAPC=–3.33%, P < 0.001), whereas salivary duct carcinoma (AAPC = 10.41%, P < 0.001) and carcinoma ex pleomorphic adenoma (APC = 2.20%, P = 0.022) showed increasing trends. Female-focused subgroup analyses demonstrated increasing incidence in both age groups: females aged ≥ 60 years (APC = 0.64%, P = 0.012) and those aged < 60 years (APC = 0.88%, P = 0.009). Mucoepidermoid carcinoma also exhibited an increasing trend among females (APC = 0.87%, P = 0.016). These findings indicate a significant increase in MSGC incidence in the US, with distinct demographic and clinicopathological patterns.